Latest On Silence Therapeutics plc (SLNCF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2020-12-31 02:57 EST | Financials | Company financials have been released. | Neutral |  |
| 2020-12-04 18:58 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-27 00:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 19:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-08 20:35 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 16:20 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-22 03:55 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 08:59 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-16 02:59 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-15 04:57 EST | News | Silence Therapeutics reports 1H results | N/A | |
| 2020-09-15 04:57 EST | News | Silence Therapeutics plc 2020 Q2 - Results - Earnings Call Presentation | N/A | |
| 2020-09-15 04:57 EST | News | Silence Therapeutics Plc (SLNCF) Mark Rothera on Q2 2020 Results - Earnings Call Transcript | N/A | |
| 2020-08-14 12:24 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 16:04 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-04 19:20 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 11:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 04:08 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 20:19 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 08:12 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 00:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-28 16:31 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 23:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 16:02 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 20:51 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 12:15 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 07:13 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-02 23:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 19:52 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 03:45 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-25 07:06 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-19 15:45 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-14 07:57 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 09:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-07 19:30 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-05 15:13 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-03 19:07 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-27 08:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-21 04:18 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-07 03:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-06 08:55 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-02 23:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-01 19:43 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-30 07:12 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-24 08:39 EST | News | Silence Therapeutics reports FY results | N/A | |
| 2020-04-24 08:39 EST | News | Silence Therapeutics' (SLNCF) Management on Q4 2019 Results - Earnings Call Transcript | N/A | |
| 2020-04-23 10:59 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-23 07:08 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-23 03:22 EST | Financials | Company financials have been released. | Neutral | |
About Silence Therapeutics plc (SLNCF):
Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various product candidates, including SLN124 for the treatment of iron overload disorders; SLN360 for the cardiovascular disease with high lipoprotein; and SLN500 for the treatment of complement-mediated diseases. Silence Therapeutics plc has a strategic collaboration with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and collaboration with Genomics England Limited. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.
General
- Name Silence Therapeutics plc
- Symbol SLNCF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 46
- Last Split Factor1:50
- Last Split Date2013-04-30
- Fiscal Year EndDecember
- Web URLhttp://www.silence-therapeutics.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 194.4
- Price/Book (Most Recent Quarter) 17.89
- Enterprise Value Revenue 283.56
View More
Financials
- Most Recent Quarter 2020-06-30
- Return on Assets -26%
- Return on Equity -82%
- Earnings Per Share -$0.09
- Revenue Per Share $0
- Gross Profit -13092000
- Quarterly Earnings Growth 0%
View More
Highlights
- Market Capitalization 690.79 million
- Book Value Per Share $0.83
View More
Share Statistics
- Shares Outstanding 89.4 million
- Shares Float 35.84 million
- % Held by Insiders 4932%
- % Held by Institutions 17.43%
View More
Technicals
- Beta 1.16
- 52 Week High $8.64
- 52 Week Low $4.25
- 50 Day Moving Average 8.05
- 200 Day Moving Average 6.49
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Silence Therapeutics plc (SLNCF) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Silence Therapeutics plc (SLNCF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 | Jun 30 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | N/A | 2.53 million |
| Income Before Tax | N/A | N/A | N/A | N/A | -4.8 million |
| Selling General Administrative | N/A | N/A | N/A | N/A | 2.33 million |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Ebit | N/A | N/A | N/A | N/A | -4.85 million |
| Operating Income | N/A | N/A | N/A | N/A | -4.85 million |
| Income Tax Expense | -1.15 million | -1.15 million | -950000 | -950000 | -694000 |
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | 55000 |
| Net Income From Continuing Operations | N/A | N/A | N/A | N/A | -4.11 million |
| Net Income Applicable to Common Shares | -5.51 million | -5.51 million | -5.69 million | -5.69 million | -4.11 million |
Cash Flow:
| Date | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 | Jun 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | N/A | N/A |
| Change to Liabilities | 23.78 million | 23.78 million | 11.08 million | 11.08 million | -550000 |
| Total Cash Flow from Investing Activities | -10.31 million | -10.31 million | -7.51 million | -7.51 million | 1000 |
| Net Borrowings | N/A | N/A | N/A | N/A | N/A |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | N/A | 100000 |
| Change to Operating Activities | -590500 | -590500 | -56000 | -56000 | 75000 |
| Change in Cash | N/A | N/A | N/A | N/A | -4.99 million |
| Total Cash from Operating Activities | 418000 | 418000 | 5.99 million | 5.99 million | -5.13 million |
| Depreciation | N/A | N/A | N/A | N/A | 128500 |
| Other Cash Flow from Investing Activities | -104500 | -104500 | -6500 | -6500 | 3500 |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | -906000 | -906000 | 545500 | 545500 | -674500 |
| Capital Expenditures | N/A | N/A | N/A | N/A | 2500 |
Balance Sheet:
| Date | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 | Jun 30 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 72.46 million | N/A | 25.17 million | N/A | 2.86 million |
| Total Stockholder Equity | 27.62 million | N/A | 20.91 million | N/A | 27.16 million |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A |
| Total Assets | 100.09 million | N/A | 46.08 million | N/A | 30.02 million |
| Common Stock | N/A | N/A | 3.92 million | 3.92 million | 3.61 million |
| Other Current Assets | 2.07 million | 4.14 million | 885000 | N/A | 774000 |
| Retained Earnings | -162.91 million | -162.91 million | -152 million | -152 million | -141.31 million |
| Other Liabilities | N/A | 63.23 million | 15.52 million | 15.52 million | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A |
| Cash | 10.32 million | N/A | 13.52 million | N/A | 11.51 million |
| Total Current Liabilities | 9.23 million | N/A | 9.65 million | N/A | 2.86 million |
| Other Stockholder Equity | N/A | 186.4 million | 30.84 million | 30.84 million | 164.86 million |
| Property, Plant & Equipment | N/A | 832000 | 611000 | 611000 | 840000 |
| Total Current Assets | 90.7 million | N/A | 37.47 million | N/A | 20.75 million |
| Long Term Investments | N/A | N/A | N/A | N/A | 275000 |
| Net Tangible Assets | N/A | 19.36 million | 13.18 million | 13.18 million | 19.01 million |
| Short Term Investments | 40.02 million | N/A | 20 million | N/A | 5 million |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 4.71 million | N/A | 6.89 million | N/A | 2.86 million |
Silence Therapeutics plc (SLNCF) Chart:
Silence Therapeutics plc (SLNCF) News:
Below you will find a list of latest news for Silence Therapeutics plc (SLNCF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Silence Therapeutics plc (SLNCF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Silence Therapeutics plc (SLNCF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|